Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:ATXI NASDAQ:BPTH NASDAQ:CFRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03$0.06$0.00▼$0.78$1.42M1.175,440 shs199 shsATXIAvenue Therapeutics$0.42+17.1%$0.26$0.17▼$3.93$1.34M-0.08129,983 shs8,345 shsBPTHBio-Path$0.16-1.3%$0.18$0.12▼$3.39$1.30M-0.03984,211 shs38,129 shsCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-77.38%-72.32%+5.21%-77.80%ATXIAvenue Therapeutics+17.06%+15.07%+61.85%+58.43%-88.11%BPTHBio-Path-1.27%-7.14%-17.68%-5.45%-91.92%CFRXContraFect0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATXIAvenue Therapeutics2.1106 of 5 stars0.04.00.04.61.00.01.9BPTHBio-Path0.9038 of 5 stars0.05.00.00.00.60.01.3CFRXContraFectN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AATXIAvenue Therapeutics 0.00N/AN/AN/ABPTHBio-Path 0.00N/AN/AN/ACFRXContraFect 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.44N/AN/A($2.06) per share-0.02ATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ABPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACFRXContraFectN/AN/AN/AN/A($19.92) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AATXIAvenue Therapeutics-$10.38M-$7.490.02∞N/AN/A-471.57%-296.50%8/7/2025 (Estimated)BPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)CFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/ACFRXContraFectN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AATXIAvenue TherapeuticsN/A2.702.70BPTHBio-PathN/A0.860.86CFRXContraFectN/A0.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ATXIAvenue Therapeutics17.34%BPTHBio-Path5.74%CFRXContraFect7.85%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ATXIAvenue Therapeutics1.80%BPTHBio-Path0.72%CFRXContraFect0.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableBPTHBio-Path108.31 million5.73 millionOptionableCFRXContraFect2310.70 million10.64 millionNot OptionableCFRX, ADXS, ATXI, and BPTH HeadlinesRecent News About These Companies22R.BE,0P0001D9RF,0 (22R.BE)September 22, 2024 | nz.finance.yahoo.comRegenETP, Inc. (RGTPQ)April 16, 2024 | finance.yahoo.comContraFect files patent for antibacterial lysin-amp polypeptide constructs and compositionsMarch 6, 2024 | pharmaceutical-technology.comPContraFect Corp CFRXQJanuary 9, 2024 | morningstar.comMContraFect Corp CFRXNovember 19, 2023 | morningstar.comMContraFect: Q3 Earnings SnapshotNovember 14, 2023 | washingtonpost.comWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketOctober 23, 2023 | benzinga.comWhy Is ContraFect (CFRX) Stock Up 23% Today?October 16, 2023 | msn.comContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyOctober 16, 2023 | finance.yahoo.comWhy Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketOctober 10, 2023 | benzinga.comCFRX: IND Application for CF-370 Submitted to FDA…September 21, 2023 | finance.yahoo.comContraFect submits IND for novel intravenous antibioticSeptember 19, 2023 | cidrap.umn.eduCAnalysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)September 19, 2023 | markets.businessinsider.comContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentSeptember 19, 2023 | finance.yahoo.comContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370September 18, 2023 | finance.yahoo.comContraFect to Present at the World Anti-Microbial Resistance Congress 2023August 28, 2023 | finance.yahoo.comCFRX: CF-370 IND to be Filed in 3Q23…August 17, 2023 | finance.yahoo.comContraFect (CFRX) Receives a Buy from Maxim GroupAugust 15, 2023 | markets.businessinsider.comContraFect: Q2 Earnings SnapshotAugust 14, 2023 | sfgate.comContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCFRX, ADXS, ATXI, and BPTH Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.03 0.00 (0.00%) As of 07/17/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Avenue Therapeutics NASDAQ:ATXI$0.42 +0.06 (+17.06%) As of 07/18/2025 03:57 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Bio-Path NASDAQ:BPTH$0.16 0.00 (-1.27%) As of 07/18/2025 03:34 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.ContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
